Xunliang Tong1, Xiaomao Xu1, Guoyue Lv2, He Wang1, Anqi Cheng3,4,5,6, Dingyi Wang7,8, Guohui Fan7,8, Yue Zhang1, Yanming Li9. 1. Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology, the Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China. 2. First Department of Hepatobiliary & Pancreas Surgery, The First Hospital, Jilin University, Jilin, 130021, Changchun, China. 3. Tobacco Medicine and Tobacco Cessation Center, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China. 4. WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention, Beijing, China. 5. National Clinical Research Center for Respiratory Diseases, Beijing, China. 6. Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China. 7. Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China. 8. Institute of Respiratory Medicine, Chinses Academy of Medical Sciences; National Clinical Research Center for Respiratory Disease, Beijing, China. 9. Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology, the Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China. lymyl@263.net.
Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that rapidly spreads worldwide and co-infection of COVID-19 and influenza may occur in some cases. We aimed to describe clinical features and outcomes of severe COVID-19 patients with co-infection of influenza virus. METHODS: Retrospective cohort study was performed and a total of 140 patients with severe COVID-19 were enrolled in designated wards of Sino-French New City Branch of Tongji Hospital between Feb 8th and March 15th in Wuhan city, Hubei province, China. The demographic, clinical features, laboratory indices, treatment and outcomes of these patients were collected. RESULTS: Of 140 severe COVID-19 hospitalized patients, including 73 patients (52.14%) with median age 62 years were influenza virus IgM-positive and 67 patients (47.86%) with median age 66 years were influenza virus IgM-negative. 76 (54.4%) of severe COVID-19 patients were males. Chronic comorbidities consisting mainly of hypertension (45.3%), diabetes (15.8%), chronic respiratory disease (7.2%), cardiovascular disease (5.8%), malignancy (4.3%) and chronic kidney disease (2.2%). Clinical features, including fever (≥38 °C), chill, cough, chest pain, dyspnea, diarrhea and fatigue or myalgia were collected. Fatigue or myalgia was less found in COVID-19 patients with IgM-positive (33.3% vs 50/7%, P = 0.0375). Higher proportion of prolonged activated partial thromboplastin time (APTT) > 42 s was observed in COVID-19 patients with influenza virus IgM-negative (43.8% vs 23.6%, P = 0.0127). Severe COVID-19 Patients with influenza virus IgM positive have a higher cumulative survivor rate than that of patients with influenza virus IgM negative (Log-rank P = 0.0308). Considering age is a potential confounding variable, difference in age was adjusted between different influenza virus IgM status groups, the HR was 0.29 (95% CI, 0.081-1.100). Similarly, difference in gender was adjusted as above, the HR was 0.262 (95% CI, 0.072-0.952) in the COX regression model. CONCLUSIONS: Influenza virus IgM positive may be associated with decreasing in-hospital death.
BACKGROUND:Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that rapidly spreads worldwide and co-infection of COVID-19 and influenza may occur in some cases. We aimed to describe clinical features and outcomes of severe COVID-19patients with co-infection of influenza virus. METHODS: Retrospective cohort study was performed and a total of 140 patients with severe COVID-19 were enrolled in designated wards of Sino-French New City Branch of Tongji Hospital between Feb 8th and March 15th in Wuhan city, Hubei province, China. The demographic, clinical features, laboratory indices, treatment and outcomes of these patients were collected. RESULTS: Of 140 severe COVID-19 hospitalized patients, including 73 patients (52.14%) with median age 62 years were influenza virusIgM-positive and 67 patients (47.86%) with median age 66 years were influenza virusIgM-negative. 76 (54.4%) of severe COVID-19patients were males. Chronic comorbidities consisting mainly of hypertension (45.3%), diabetes (15.8%), chronic respiratory disease (7.2%), cardiovascular disease (5.8%), malignancy (4.3%) and chronic kidney disease (2.2%). Clinical features, including fever (≥38 °C), chill, cough, chest pain, dyspnea, diarrhea and fatigue or myalgia were collected. Fatigue or myalgia was less found in COVID-19patients with IgM-positive (33.3% vs 50/7%, P = 0.0375). Higher proportion of prolonged activated partial thromboplastin time (APTT) > 42 s was observed in COVID-19patients with influenza virusIgM-negative (43.8% vs 23.6%, P = 0.0127). Severe COVID-19Patients with influenza virusIgM positive have a higher cumulative survivor rate than that of patients with influenza virusIgM negative (Log-rank P = 0.0308). Considering age is a potential confounding variable, difference in age was adjusted between different influenza virusIgM status groups, the HR was 0.29 (95% CI, 0.081-1.100). Similarly, difference in gender was adjusted as above, the HR was 0.262 (95% CI, 0.072-0.952) in the COX regression model. CONCLUSIONS:Influenza virusIgM positive may be associated with decreasing in-hospital death.
Authors: Trevor Bedford; Steven Riley; Ian G Barr; Shobha Broor; Mandeep Chadha; Nancy J Cox; Rodney S Daniels; C Palani Gunasekaran; Aeron C Hurt; Anne Kelso; Alexander Klimov; Nicola S Lewis; Xiyan Li; John W McCauley; Takato Odagiri; Varsha Potdar; Andrew Rambaut; Yuelong Shu; Eugene Skepner; Derek J Smith; Marc A Suchard; Masato Tashiro; Dayan Wang; Xiyan Xu; Philippe Lemey; Colin A Russell Journal: Nature Date: 2015-06-08 Impact factor: 49.962
Authors: Zhou Guan; Can Chen; Yiting Li; Danying Yan; Xiaobao Zhang; Daixi Jiang; Shigui Yang; Lanjuan Li Journal: Front Public Health Date: 2021-12-10
Authors: John McCauley; Ian G Barr; Terry Nolan; Theodore Tsai; Steven Rockman; Beverly Taylor Journal: Influenza Other Respir Viruses Date: 2021-10-03 Impact factor: 5.606